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Abstract:
Background: Acute toxoplasmosis in pregnant women presents a high risk of  Toxoplasma transmission to the fetus. Early di-
agnosis is difficult, especially when serological testing for IgG/IgM antibodies fail to differentiate between a recent and a past 
infection. In this case, we rely on IgG avidity or PCR assays.
Objectives: The aim of  this study was to compare conventional ELISA and IgG avidity, with PCR using B1 and P30 primers 
for the early diagnosis of  toxoplasmosis in pregnant women.
Methods: Sera were collected from 143 pregnant women and measured by ELISA for anti-Toxoplasma IgG, IgM, IgA and IgG 
avidity. DNA was extracted from 57 peripheral blood and 14 amniotic fluid samples for PCR amplification. 
Results: A total of  57 out 143 women were seropositive: 30 (52.6%) were IgG+/IgM- and 27 (43.8%) were IgG+/IgM+; IgA 
antibodies were positive in 7 (12.2%) cases. IgG avidity was low in 9 women suggesting an acute infection; 3 women presented 
an intermediate avidity. PCR detected Toxoplasma DNA in 9 women presenting low avidity and was negative for the intermediate 
avidity cases.
Conclusion: PCR combined to avidity IgG performed better than ELISA IgG, IgM and/or IgA assays alone. PCR was useful 
in the case of  intermediate avidity.
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Toxoplasmosis, caused by the intracellular parasite Toxo-
plasma gondii (T gondii), is one of  the most prevalent dis-
eases in humans1. This disease is generally asymptomatic 
in immunocompetent human host2. However, T gondii 
causes substantial morbidity and mortality in immuno-
compromised patients3,4 and in congenitally infected in-
fants5. Infection acquired by pregnant women immediate-
ly before or during gestation and its transmission to the 
fetus continues to be the cause of  tragic yet preventable 
diseases, which may be more or less severe depending on 
the date of  transmission6. Congenital infection acquired 
during the early stages of  pregnancy often results in se-
vere fetal signs such as severe neurological damages, or 
fetal death. Infection acquired later, within the second or 
third trimester, is more likely to be asymptomatic at birth 
leading usually to much less severe injury of  the newborn 
and later of  the child7. A rapid and accurate diagnosis is 
required in order to start the relatively efficient anti-par-
asitic treatment8.
Current diagnosis of  toxoplasmosis relies mainly on sero-
logical detection of  specific IgG and IgM, on fibroblast 
cell culture or mice inoculation of  amniotic fluid or fetal 
blood3,9. The presence of  IgM is, in general, an indication 
that the host has recently been infected. However, these 
antibodies can persist for months or even years after 
acute infection. Consequently, the concomitant presence 
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of  IgM and IgG does not always indicate an acute infec-
tion, so it is necessary to study antibody kinetics based 
on a serological control 2-3 weeks later10. Moreover, sero-
logical testing may fail during the active phase of  T. gondii 
infection because the antibodies titres are low; therefore, 
the high risk of  congenital toxoplasmosis of  a fetus may 
be undetected because the pregnant mother might test 
negative during the active phase of  T. gondii infection. 
When high levels of  IgG antibodies are present in sera, 
serological testing does not distinguish a recent infection 
from one acquired a longtime before and detection of  
specific IgM response cannot help determine if  infection 
was recent11. This inconvenience has limited the use of  
the serological tests. More studies have shown that IgG 
avidity assay10,14,15 or polymerase chain reaction (PCR)12,13 
are useful for identification or exclusion of  T. gondii acute 
infection, or for estimation at the time of  seroconversion.
In this study, IgG avidity and PCR have been evaluated, 
on the basis of  the results obtained with conventional 
serological tests, as a diagnostic tool for the diagnosis of  
toxoplasmosis in Algerian pregnant women, and for the 
descrimination between acute and chronic infection.
 
Patients and methods:  
This prospective study was carried out at Abdallah 
Nouaouria Hospital, El Bouni-Annaba. Peripheral blood 
(PBL) and amniotic fluid (AF) samples were collected 
during diagnosis for toxoplasmosis in 143 pregnant wom-
en, between 22 and 43 years old. None of  the mothers 
had apparent symptoms of  toxoplasmosis during their 
pregnancy and no antibiotic drugs were previously pre-
scribed to the patients. Two blood samples, with respec-
tively an interval of  21 days, were taken from each pa-
tient. Therefore, a total of  286 sera samples were checked 
for anti-Toxoplasma antibodies by serological tests : IgG, 
IgM and IgA ELISA assay. A total of  57 samples (one 
sample from each patient) with a positive anti-Toxoplasma 
IgG were further analysed using the IgG avidity. Blood 
and AF samples were taken for DNA extraction. Gene 
amplification was processed on 57 PBL samples; PCR on 
AF was done to 14 women suspected to have acute infec-
tion which can lead to a congenital toxoplasmosis. This 
study was approved by the Hospital Ethical Committee, 
and informed consent was obtained from all the patients.
IgG, IgM and IgA ELISA 
All patients’ sera were tested for the presence of  specif-
ic IgG, IgM and IgA antibodies to Toxoplasma using an 
ELISA kits (Platélia Toxo, Diagnostic Pasteur, France) ac-
cording to the manufacturer’s instructions. The anti-Toxo-
plasma IgG, expressed in IU, were calculated from a stan-
dard curve. « Double sandwich » ELISA was used for the 




The Toxoplasma-specific IgG avidity assay was performed 
by ELISA (SFRI® laboratoire, France) to discriminate 
between acute and chronic infection. A total of  57 sera 
samples were diluted 1/200 and added (100 μl/well) on 
2 rows of  a plate (row A and row B). After 45 min of  
incubation at 37°C, the row B was washed 3 times with 
the modified PBST buffer containing 6 M urea and 4 
times with PBST containing 0.05% Tween 20 in order 
to remove low-avidity antibodies from their binding sites. 
The control row A was washed 3 times with buffer with-
out urea. The anti-human IgG conjugated with horse-
radish peroxidase (Dako Glostrup, Denmark) was added 
with the dilution of  1/1000 in PBST. After incubation 
and washing, the chromogenic substrate, O-phenylene-
diamine (Merk, Darmstadt, Germany), was added. The 
reaction was stopped by addition of  sulfuric acid 20%. 
The absorbance was read at 492 nm.  The IgG avidity 
index (AI: %)  was calculated on the basis of  the formula :
AI = Abs (PBS-urea)/Abs(PBST) ×100.
Three different avidity classes were determined: AIs low-
er than 25%, between 25% and 35%, and above 35% 
were classified as low, intermediate, and high avidity, re-
spectively.
 
DNA parasite preparation     
DNA extracted from the tachyzoites of  T. gondii-RH strain 
(Institut Pasteur, Tunis)  was used as positive control for 
PCR. The parasites were harvested from the peritoneal 
exudate of  Swiss-Webster female mouse intraperitoneally 
infected 3 days earlier. The DNA parasite was extract-
ed using the salting out method. The concentration of  
purified DNA was mesured by UV spectrophotometry 
(GENEQUANT, pharmacia Biotech). The DNA sam-
ples were stored at -20°C.
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Polymerase chain reaction of  T. gondii B1 and P30 
genes 
PBL and AF DNA were extracted by the salting out 
method using the Sodium Chlorure 6 M and precipitated 
with ethanol16. The DNA pellet was dissolved in TE buf-
fer and concentrations were then determined.
PCR amplification was carried out in two separate assays : 
nested PCR, using the 35-fold repetitive DNA region B1 
of  T. gondii primers sets and conventional PCR-ELISA 
using the major surface antigen P30 gene primers sets. 
The primer sequences and the expected size of  B1 and 
P30 genes PCR products are shown in Table 1.    
Table 1: B1 and P30 Genes primer sequences for the amplification of T.gondii DNA. 
  







Outer sense strand 
Outer nonsense strand 
  
Inner sense strand 
Inner nonsense strand 
  
Tx2 : TCT  TTA  AAG  CGT  TCG TGG  TC  
Tx4 : GGA  ACT  GCA  TCC  GTT  CAT  GAG  
  
Tx1 : GGC  GAC  CAA TCT  GCG  AAT  ACA 
ACC  
Tx3 : TGC  ATA  GGT  TGC  AGT  CAC  TG 
  
  
887 - 868 



















GBI5 : AGC TGG TGG ACG GGG GAT TC  
GBI6 : GTC TGC ACC GTA GGA GCA CC)  
  
  
689 - 709 





For nested PCR using the B1 gene, previously described 
by Burg17, amplification was carried out in a 50 µl reac-
tion mixture containing 10 mM Tris-HCl (pH 9.0), 50 
mM KCl, 1.5 mM MgCl2 (Promega, France), 0.2 mM of  
each dNTP (Bohringer Mennheim, Germany), 50 pmol 
of  each primer (Diasorin, Biomedica, Italy), 2.5 U of  Taq 
DNA polymerase (Promega, France)and DNA extracted 
from each sample. Reactions were run in a Perkin-Elmer 
thermocycler by using a step cycle program. After initial 
denaturation of  the DNA at 94°C for 5 min, 40 cycles 
were run : 60 s with a denaturing temperature of  94°C, 60 
s with an annealing temperature of  55°C, and 90 s with 
an extension temperature of  72°C, with a 5 min 72°C ex-
tension after the 40 cycles. After the first 40 cycles, 10 µl 
of  each sample was transferred to a second PCR reaction 
into 40 µl of  fresh mixture containing the inner primers 
pair and the procedure was repeated for 35 cycles.
The conventional PCR-ELISA was assessed for the am-
plification of  the P30 gene18 using specific primers and 
under the same conditions as B1 gene for 40 cycles.
Each amplification run included negative and positive 
controls. All samples were tested in duplicate. Amplicons 
were revealed by ethidium bromide on 2% agarose gel 
electrophoresis, and then visualized under UV illumina-
tion.
For P30 gene, detection of  hybrids was performed by 
an ELISA-PCR kit (GEN-ETI-K, DEIA, Diasorin, It-
aly) as described by the manufacturer. The solid phase 
was prepared in advance : the wells of  a microplate were 
coated with biotinylated DNA probe (5' TCCCTT GAT-
GCAACCGACCACAAA). A result was considered pos-
itive when one reaction yielded an amplification product 
hybridizing to the specific DNA probe.
Results: 
Antibody detection 
According to respective levels of  anti-Toxoplasma IgG and 
IgM in the first positive sample and in the second one, a 
Toxoplasma seropositive status during pregnancy was de-
fined  in 57 (39.8%)  women. Table 2 shows the huge 
diversity of  the techniques used and presents data on the 












Outer sense trand 
Outer nonsense strand 
 
Inner sense strand 
Inner nonsense strand 
 
Tx2 : TC   TA  AG  CGT  TCG TG   TC   
Tx4 : GGA  CT  GCA  TC   TT  CAT  AG   
 
Tx1 : GGC  GAC  CAA TCT  GCG  AAT  ACA ACC   
Tx3 : TGC  ATA  GGT  TGC  AGT  CAC  TG  
 
 
887 - 868 
694 - 714 
 
853 - 831 
757 - 776 
 
193   
 
 










GBI5 : AGC TGG TGG ACG GGG GAT TC   
GBI6 : GTC TGC ACC GTA G A GCA C )   
  
 
689 - 709 
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Table 2: Serological (ELISA) 
and molecular (PCR) results from 57 Toxoplasma seropositifs pregnant women 
  
  
  Patient 
N° 
  














Diagnosis Blood AF Blood AF 
 1 16 + +    220 18 AI +/- -/- +/+ -/- 
 2 16 - +  >240 63 CI -/-   -/-   
 3 20 - -  >240 67 CI -/-   -/-   
 4 16 + +  >240 15 AI +/+ -/- +/+ -/- 
 5 15 - +  >240 71 CI -/- -/- -/- -/- 
 6 16 - +  >240 65 CI -/-   -/-   
 7  8 - +  >240 20 AI +/+   +/+   
 8 19 - +  >240 58 CI -/-   -/-   
 9 12 - -  >240 47 CI -/-   -/-   
10 12 - -  >240 62 CI -/-   -/-   
11 16 - +  >240 55 CI -/-   -/-   
12 13 - -  >240 49 CI -/-   -/-   
13 16 - +    114 44 CI -/- -/- -/- -/- 
14 14 - +  >240 28 IA -/- -/- -/- -/- 
15 15 + +  >240 21 AI +/+ +/+ +/+ +/+ 
16  8 - +    129 70 CI -/-       
17 16 - -      80 59 CI -/-   -/-   
18  6 - -  >240 65 CI -/-   -/-   
19 16 - -    110 51 CI -/-   -/-   
20 16 - -  >240 53 CI -/-   -/-   
21 12 - +  >240 48 CI -/-   -/-   
22  8 - +    125 47 CI -/-   -/-   
23 13 - -    110 52 CI -/-   -/-   
24 15 - +    180 31 IA -/- -/- -/- -/- 
25 16 - +    240 68 CI -/- -/- -/- -/- 
26 14 - -      80 60 CI -/-   -/-   
27 10 + +    240 14 AI +/+   +/+   
28  8 - -    112 52 CI -/-   -/-   
29 15 + +  >240 16 AI +/+ +/+ +/+ +/+ 
30 16 - -  >240 42 CI -/-   -/-   
31 12 - -    180 47 CI -/-   -/-   
32 14 - -    220 51 CI -/-   -/-   
33 14 - +  >240 68 CI -/-   -/-   
34 16 + +  >240 20 AI +/+ +/- +/+ +/+ 
35 13 - -  >240 43 CI -/-   -/-   
36 15 - +  >240 44 CI -/- -/- -/- -/- 
37 11 - -    220 71 CI -/-   -/-   
38 13 - -    240 65 CI -/-   -/-   
39 18 - -  >240 49 CI -/-   -/-   
40 12 - -    118 46 CI -/-   -/-   
41 16 - -    200 29 IA -/- -/- -/- -/- 
42 12 - +    180 39 CI -/-   -/-   
43 15 - +  >240 19 AI +/+ -/- +/+ -/- 
44 10 - -  >240 61 CI -/-       
45 14 - -  >240 42 CI -/-   -/-   
46 11 - -    140 43 CI -/-   -/-   
47  8 - -    220 52 CI -/-   -/-   
48 10 - +    240 41 CI -/-   -/-   
49  9 - -  >240 42 CI -/-   -/-   
50 11 - -  >240 52 CI -/-   -/-   
51 12 - +    220 46 CI -/-   -/-   
52 12 - -  >240 44 CI -/-   -/-   
53 15 - -    240 46 CI -/-   -/-   
54 16 + +    114 20 AI +/+ +/+ +/+ +/+ 
55 17 - -  >240 55 CI -/-   -/-   
56 10 - +    240 51 CI -/-   -/-   
57  9 - -  >240 50 CI -/-   -/-   
  
AI: Acute Infection, CI: Chronic Infection, IA: Intermediate Avidity, AF: Amniotic Fluid, IU: International Unit 
Duplicate assays results are given for DNA amplification. 
The IgG ELISA antibodies were evaluated with the fol-
lowing IU:between 80 and 220 in 20 women (35%) and 
240 in 37 women (64.9%). For IgM antibodies, 27 (47.3%) 
of  57 cases tested positive with high titers. The IgA anti-
bodies were found in 7 out of  57 (12.2%) samples (Tab. 
3).
T ble 2: S rological (ELISA) and molecular (PCR) results fr m 57 Toxopl sma seropositifs pregnant women 
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Table 
3: Ratesof Toxoplasma acute infection among the study pregnant women. Diagnosis was performed 
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Nbr     (%) 
  
IgA 
Nbr     (%) 
  
IgM 
Nbr     (%) 
  
  
LowAvidity           Nbr 
    (%) 
  
Blood 
Nbr     (%) 
  
AF 
Nbr     (%) 
  
Blood 
Nbr     (%) 
  
AF 




  1/57     (1.75)   
  




  4/57    (7.01)         
  
1/57   (1.75) 
      
  
 0/14    (0.00)      
  
1/57   (1.75) 
     
  
0/14     (0.00) 
      
  





7/57    (12.28)  
      
  
15/57   (26.31) 
        
  
5/57    (8.77)         
  
8/57  (14.03)     
   
  
4/14   (28.57)  
      
  
8/57   (14.03)  
     
  
4/14   (28.57)   
    
  
  8/57    (14.03) 
AF : Amniotic Fluid 
AI : Acute Infection 
Among the 57 women, a total of  30 (52,6%) sera were 
IgG+/IgM−, while 27 (47.3%) sera were IgG+/IgM+. 
No sera sample was IgG−/IgM+.
A possible acute infection was suspected for 14 women 
on the basis of  a combination of  positive specific IgG/
IgM and/or IgA, using two blood samples from each pa-
tient, with respectively an interval of  21 days.
IgG Avidity 
Toxoplasma IgG Avidity assay has been performed on 57 
sera with IgG positive results. High avidity antibodies 
(indicative of  chronic toxoplasmosis) were present in 45 
(78.9%) women ; intermediate avidity was determined for 
3 (5.2%) women and low IgG avidity antibodies (indic-
ative of  acute toxoplasmosis) were found in 9 (15.7%) 
women, without evidence of  Toxoplasma infection (Tab. 
2). Therefore, 9 out 14 suspected infected women showed 
low IgG avidity which confirmed an acute infection.
Women, with positive IgM and IgA, were shown to be 
recently infected indicating an active toxoplasmosis in-
fection (Tab. 2). All subjects presenting an acute toxo-
plasmosis were at least in the first (1 women out 9) or 
second (8 women out 9) trimesters of  their pregnancies. 
Therefore, toxoplasmosis infection occurred most likely 
before or just after conception with a substantial risk for 
the fetus.
 
Polymerase chain reaction assay 
The PCR results are summarized in Table 2. T.gondii DNA 
was detected by PCR targeting of  the B1 and P30 genes 
in 9 of  57 (15.7%) blood samples and 4 of  14 (28.5%) AF 
samples obtained from pregnant women. PCR positive 
results with the AF samples demonstrated a congenital 
toxoplasmosis. A total of  8 women out 9 were in the sec-
ond trimester of  their pregnancies (Tab. 3).
All the PCR positive cases were seropositive ; these in-
cluded 7 samples (12.2%) that were positive for IgG, IgM 
and IgA antibodies and 2 (3.5%) samples that were pos-
itive for both IgM and IgG antibodies. A high IgG avid-
ity and a negative PCR results excluded recent Toxoplas-
ma infection in the other women. With regard to positif  
PCR and low IgG avidity results, 7/9  patients have an 
IgG-ELISA value   240 IU and a positive IgA antibodies.
Viewed separately, IgG avidity alone didn’t demonstrate 
the acute or chronic infectious status in 3 women who 
showed an intermediate IgG avidity, whereas PCR gave 
negative signals with both gene targets and demonstrate a 
chronic infectious status for these women.
The PCR-ELISA targeting the P30 gene had a lowest 
sensitivity compared to the nested PCR targeting the 
B1 gene. In fact, when PBL and AF samples were used, 
only one assay out of  two duplicate tests returned posi-
tive  (patients 1 for PBL samples and patients 15 and 34 
for AF). No PCR product was obtained with the negative 
controls in any experiment.
 
Discussion: 
When a T. gondii primary infection is acquired during 
pregnancy, the parasite may be transmitted to the fetus. 
The parasite reaches the fetus transplacentally, causing 
various degrees of  damages, depending on: the virulence 
of  the parasite, the immune response of  the mother and 
at what trimester the infection was acquired, resulting 
in fetal death or in severe clinical symptoms6. Pregnant 
Table 3: Rates of Toxoplasma acute infection among the study pregnant women. Diagnosis  
was performed on blood and amniotic fluid samples.        
≥ 
Trimester
Serological Results PCR Results

















First 1/57 (1.75)   12/57     (21.05) 4/57 (7.01)         1/57      (1.75)       0/14  (0.00)      1/57      (1.75)      0/14     (0.00)       1/57      (1.75)
Second 7/57      (12.28)        15/57     (26.31)       5/57     (8.77)         8/57     (14.03)        4/14   (28.57)        8/57     (14.03)       4/14   (28.57)       8/57   (14.03)
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women are frequently asymptomatic, making a diagnosis 
difficult. Determination of  recently acquired T. gondii in-
fection in pregnant women must be made as early as pos-
sible to begin an adequate anti-parasitary treatment wich 
can improve the prognosis19.
Currently, the diagnosis of  toxoplasmosis is based on im-
munological testing that give the titer of  circulating an-
tibodies. The presence of  specific, IgM20 or IgA,21,22 may 
help to identify recent infection. However, increased lev-
els of  IgG and IgM antibodies do not distinguish a recent 
infection from one acquired a long time before. Therefor, 
a rapid and effective diagnosis is crucial to initiate an ad-
equate treatment.
In the present study, the tests we used for clarifying the 
serological status of  pregnant women showed IgG and/
or IgM anti-Toxoplasma antibodies for 57 (39.8%)  out 143 
women, which represent the global prevalence of  anti-T 
gondii IgG antibodies in this population.  Toxoplasma infec-
tion during pregnancy was suspected among 14 women 
according to respective level of  anti-Toxoplasma IgG and 
IgM in the first and second samples. On the other hand, 
results revealed higher IgA antibody titers from acute-
ly infected pregnant women which indicates that in the 
presence of  Toxoplasma specific IgG and IgM antibodies, 
the additional presence of  IgA was sufficient to identify 
the acquisition of  infection within the previous 8 to 16 
weeks. There is an association between the high level of  
IgA and IgM which may indicate acute phase of  toxoplas-
mosis. It has faster kinetics, suggesting that the infection 
occurred less than eight months previously23,24. IgA anti-
body determination seems to be important for screening 
of  pregnant women and for prenatal diagnosis.
When using the presence of  specific IgM as criteria for 
identifying T. gondii infection in early pregnancy, many 
women will be falsely identified as possibly infected and 
unnecessarily undergo diagnostic amniocentesis and anti-
parasitic treatment. In fact, true positive results must be 
carefully interpreted25 as IgM antibodies might persist for 
years after primary infection (residual IgM)11,26. This fact 
has limited the use of  these methods, because it is not 
possible to determine if  the patient has an acute infection 
or if  the infection had occurred months before27. Sero-
logical testing may fail during the active phase of  T. gondii 
infection because the antibodies titres are low; therefore, 
the high risk of  congenital toxoplasmosis of  a fetus may 
be undetected because the pregnant mother might test 
negative during the active phase of  T. gondii infection. 
The ideal situation for the diagnosis of  Toxoplasma infec-
tion in pregnancy would be to have an antibody-negative 
sera sample collected before conception  or at the begin-
ning of  pregnancy. However, this was not possible in this 
study.
In combination with the serological conventional tests, 
IgG avidity is an auxiliary test which permits to differ-
entiate past and present Toxoplasma infection when the 
IgM serological reaction is positive in an asymptomatic 
patient28,29,30. In 1989, Hedman et al.28 introduced the IgG 
avidity methode for detecting recently acquired Toxoplas-
ma infection, based on the strength of  the binding of  
specific IgG to multivalent Toxoplasma antigen31 and than 
on the elution of  low avidity antibodies by a protein-de-
naturing agent, mostly urea32,33. During the course of  the 
immune response, there is maturation of  antibody affini-
ty that increases progressively over weeks or months. In-
crease in IgG affinity result from an antigen-driven B-cell 
selection process, resulting in an increase in complemen-
tarity of  the antigene-antibody-binding site34. This bind-
ing strength was found to be low in acute phase and high 
in chronic phase of  toxoplasmosis35,36; therefore, detec-
tion of  a low IgG avidity is a reliable indicator for recent 
toxoplasmosis, whereas a high avidity shows that the in-
fection occurred in the previous 4-5 months37,38. This is 
most useful in pregnant women in their first months of  
gestation who have a positive test for both IgG and IgM 
Toxoplasma antibodies34. In this study, recent infection 
in 9 pregnant women was confirmed by the low avidity 
index found by IgG avidity ELISA. In fact, we showed 
that a low avidity index associated with IgG, IgM and/or 
IgA seroreactivity, is a good indicator that an acute T. gon-
dii infection within the last 4 months has been occured. 
Among 57 seropositive women, the measure of  avidity 
on the first sera sample have allowed us to take accurate 
conclusions in 94.7% of  cases. The antibody assay com-
binations and comparison between conventional ELISA 
and IgG avidity have proven to be very useful. Lecolier 
and Pucheu,39 concluded that the Toxoplasma-specific IgG 
avidity test should be performed with the first blood sam-
ple collected in early pregnancy to exclude acute infection 
during gestation.
For three patients the avidity index showed a border 
line result. When avidity is low or borderline it may be 
misleading and a more careful interpretation is critical. 
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Low-avidity results may persist for as long as 1 year and 
should not be considered as a sufficient argument to con-
firm a recent seroconversion and even less to prescribe 
invasive procedures like amniocentesis34. In these cases 
direct detection of  the parasite is necessary for a defini-
tive diagnosis.
The use of  the PCR test enable the rapid detection of  
specific Toxoplasma genes and its combination with sero-
logical tests carried out on PBL and AF, facilitate earlier 
diagnosis of  congenital toxoplasmosis. Among the many 
factors influencing the PCR outcome, the choice of  the 
DNA target and primers is generally considered as essen-
tial. Few DNA target loci have been described for Toxo-
plasma PCR, but different primer pairs have been used 
in different assays. The principal gene target remains the 
35-fold repetitive and conserved B1 gene. The detection 
level of  PCR is 1 to 10 parasites in the presence of  105 
human leucocytes17. In our study, T. gondii DNA could 
be detected in 9 women who showed positive IgG and 
IgM antibodies as well as low IgG avidity suggesting that 
these women may have acquired infection during preg-
nanacy. With regards to the PCR assay by the use of  PBL 
and AF, both B1 and P30 primer sets performed quite 
equally well and therefore appear adequate for Toxoplasma 
identification; but, with primer set P30, an additional step 
(achieved through an ELISA–PCR assay) for confirming 
the identity of  the PCR product is of  utter importance. 
However, B1 gene proved valuable PCR for T. gondii de-
tection better than P30 gene. Our results showing 3 false 
negative PCR (Tab. 2), are in agreement with those of  
Bastien40 who validate the current choice targeting B1 
gene, which appear clearly more sensitive than assays tar-
geting the single copy P30 gene. 
The PCR results were in concordance with those of  IgG 
avidity test. Moreover, PCR was very helpful in cases of  
intermediat avidity. 3 cases were IgG avidity borderline 
but PCR negative.
Based on the results of  this study, the IgG avidity and the 
PCR tests performed better than the conventional ELI-
SA for the diagnosis of  Toxoplasma infection in pregnant 
women.
When only conventional ELISA was used, 24.5% (14 of  
57) acute infections were suspected. When ELISA and 
IgG avidity were combined, 3 suspected infections out of  
14 (05.2%) yielded an intermediat avidity. When ELISA, 
IgG avidity, and PCR findings were combined, the acute 
toxoplasmosis of  pregnant women could be demon-
strated in 15.7% of  cases (9 of  57). This study confirms 
the complementary need of  the techniques used for the 
screening of  pregnant women, but some authors recom-
mend PCR than most serologic techniques13
Conclusion:
In this study, the conventional serodiagnosis of  toxoplas-
mosis, on the basis of  the first and the second sera sample, 
was sufficient to determine the serological status of  most 
women and the demonstration of  IgA antibody appears 
useful for diagnosis of  Toxoplasma infection. However, 
this is was not possible for some women. The IgG avid-
ity assay has been demonstrated to have the utility to ex-
clude recent infection in early pregnancy for women who 
otherwise, on the basis of  a positive specific IgM result, 
would have been identified as having a recent infection. 
From these results it can be concluded that IgG avidity, 
performed in single samples from positive anti-Toxoplas-
ma IgM pregnant women, is a valuable diagnostic tool. 
Overmore, single PCR-negative samples in conjunction 
with an IgG/IgM positive test result could confirm a past 
infection in the presence of  serologic results that are dif-
ficult to interprete, especially for intermediate avidity.
The main finding of  our study was the significant associa-
tion between high IgG anti-T. gondii titers, low index avid-
ity and PCR detection of  T. gondii DNA and the diagnosis 
of  acute toxoplasmosis. Moreover, the molecular biology 
technique was useful in pregnant women with serocon-
version, to exclude the presence of  T. gondii DNA in AF. 
These women will be saved from unnecessary anxiety, 
additional examinations and treatment. However, to the 
best of  our knowledge, no studies have been published 
using both IgG avidity and PCR for the diagnosis of  
toxoplasmosis on pregnant women in Algeria. We hope 
that our study will open new perspectives for the system-
atic introduction of  these techniques in the diagnosis of  
toxoplasmosis.
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